The global urinary retention therapeutics market is anticipated to attain a valuation of US$ 3.44 billion in 2023 and is projected to reach US$ 7.5 billion by 2033, trailing a CAGR of 8.11% during the forecast period.
Increasing rising prevalence of urinary incontinence (UI) and numerous factors like urinary tract infection, weakening of pelvic floor muscles and urethral sphincters, menopause, pregnancy, childbirth, and post-radical prostatectomy surgery in men leads to the development of urinary incontinence symptoms which is expected to fuel market expansion of Urinary retention therapeutics during the forecast period.
In addition, rising cases of urological disorders and development of advanced urinary incontinence devices are expected to boost the growth of urinary retention device market in the projected period. Furthermore, rising demand for minimally invasive operations, as well as aging population that is more prone to urological problems is anticipated to propel growth of the urinary retention device market. Moreover, increasing number of urinary incontinent patients switching from traditional methods to advanced methods is anticipated to rise in the coming years which benefit the market. The expansion of the market is also aided by the increasing risk of related urological disorders among people.
Report Attribute | Details |
---|---|
Expected Market Value (2023) | US$ 3.44 billion |
Anticipated Forecast Value (2033) | US$ 7.5 billion |
Projected Growth Rate (2023 to 2033) | CAGR 8.11% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The market for urinary retention was worth US$ 2.5 billion in 2018, while growing at a CAGR of 6.59 % during the historical period. An article titled “Urinary Incontinence in Postmenopausal Women (2019),” published in the National Center for Biotechnology Information (NCBI), reported that there has been an increase in the incidences of several diseases, like Parkinson's disease, diabetes, multiple sclerosis, etc., which might lead to growing prevalence of urinary incontinence in men and women. This is anticipated to create demand for urinary retention treatment devices during the forecast period. Moreover, the increasing demand for minimally invasive procedures and surging technological advancements are anticipated to fuel market expansion of Urinary retention therapeutics. Surging research and development activities in the field of Urinary Disorders is creating awareness among people and opportunities in the target market, which is anticipated to fuel the market’s growth.
In addition, the surging demand for minimally invasive procedures and mounting technological advancements are anticipated to boost market growth. Surging research and development activities in the field of bladder disorders is creating awareness among people and lucrative prospects in the concerned market. On the other hand, several market players are adopting various strategies, like product launches, developments, acquisitions and mergers, collaborations, to expand their product portfolio in Urinary retention treatment market, which is expected to fuel market growth in the forecast period.
For example, in November 2019, Renovia Inc. declared that the United States Food and Drug Administration’s clearance for its next-generation leva Pelvic Digital Therapeutic, which will be utilized for strengthening pelvic floor muscles and for treating stress, mixed and mild to moderate urgency urinary incontinence in women which will lead to market expansion in the upcoming years. Considering these factors and new developments, the revenue growth of Urinary retention treatment market is projected to be worth US$ 7.5 billion by end of the forecast period, while exhibiting a CAGR of 8.11 %.
Growing cases of prostate cancer driving market growth
Increasing demand for technologically advanced and minimally invasive OTC devices and wearables are propelling research and development activities in urinary retention devices market which is expected to drive market growth during the forecast period. Likewise, MedTech companies are keen on getting Food and drug administration approvals for their next-generation devices for treatment of stress incontinence, especially for treatment of female stress urinary incontinence. This will lead to market’s growth in the coming years.
On the other hand, surging cases of prostate cancer and the awareness of its morbidity is leading to expansion of Urinary retention market. Patients undertaking radical prostectomy surgery are at a high risk of developing post prostatectomy urinary incontinence. Also, radical prostectomy surgery, whether through radiation or surgical dissection, negatively affects the bladders capacity to hold urine or causes spasms that disturbs the urine flow. Additionally, radical prostectomy surgery adversely affects the nerves that regulate bladder function, resulting in bladder disorders. This leads to increasing demand for the devices that help in managing the disease. These factors are expected to propel market growth of Urinary retention treatment during the forecast period.
Preference for other therapies restraining market expansion
The growth of the urinary retention treatment device market is restrained by the dearth of awareness about new improvements in urinary disorders treatment devices and post-operative difficulties associated with the devices.
Moreover, increasing cost of treatment and a vulnerable aging population are two variables that negatively affect the need for urinary retention treatment medications. Also, preference for other therapy is further expected to restrain growth of urinary retention treatment market in the forecast period. The industry is also anticipated to be hampered by the surging number of incontinent patients who are unaware of their condition.
North America to dominate the market with maximum share
North America is expected to dominate the market of Urinary retention therapeutics by accounting for 49.6% market share by end of the forecast period. The growth is attributable to early adoption of technologies, vast patient pool of urinary disorder and easy availability and lucrative medical reimbursement policies in the United States and Canada.
On the other hand, strategies adopted by key companies, such as research and development, mergers & acquisitions, and product launches to bolster their market position is another driving factor for the market expansion of Urinary retention therapeutics. For example, In February 2020, Atlantic Therapeutics declared that the United States Food and Drug Administration had granted over-the-counter (OTC) clearance to ‘INNOVO’, a non-invasive, clinically proven, and wearable device for the treatment of stress urinary incontinence in adult females. Therefore, these abovementioned factors are anticipated to fuel the urinary retention treatment devices market in this region during the forecast period.
East Asia driving growth with fastest CAGR
The market in East Asia is projected to exhibit the fastest CAGR of 7.5% during the forecast period. This region offers profitable opportunities for players that operate in the urinary retention treatment devices market owing to its high population base, increasing disposable incomes, and improvements in patient awareness related to advanced urinary retention management.
Japan and China are among the leading countries for prevalence of urinary and bladder disorders in East Asia, which further contributes toward the strong growth reflected by this region in the global urinary retention devices market. Furthermore, lifestyle and demographic changes have led to increase in the cases of gynaecological problems in females at an early age that is expected to benefit the targeted market.
Also, increasing number of hysterectomy cases, surging number of women with early onset of menopause, and growth in obese population are expected to propel market growth in this region as women suffering from above mentioned health conditions are more prone to urinary disorders like urinary retention. These factors are anticipated to fuel the market growth in the forecast period.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Stress incontinence propelling growth with dominating share
By incontinence type, the stress urinary incontinence segment is expected to dominate the urinary retention therapeutics market with a market share of 38.2% by end of the forecast period. The growth is attributed to rising incidences of stress urinary incontinence witnessed among women.
The epidemiological studies on the stress urinary incontinence in women have reported that around 50% of women with urinary incontinence report symptoms of stress incontinence. Studies have also shown that the rate of stress urinary incontinence among men ranges from 2% to 70% after undergoing prostate surgery. These factors are likely to fuel the segment’s growth during the projected period.
Retail Pharmacies to drive growth with maximum market share
The retail pharmacies are expected to dominate the market by accumulating 57.5% market share by end of the forecast period. This segment is anticipated to grow with a CAGR of 7.1% during the forecast period. The dominating market share of the retail pharmacies is attributed to the long-established nature and widespread availability of these pharmacies around the world. Moreover, most of the consumers still prefer shopping at these channels as it presents product verification, authenticity, and surety. Likewise, these stores offer convenience, customization, and personal assistance to the consumers, which, in turn, is expected to drive the segment growth.
Also, retail stores are the first point of contact for companies to supply products and samples. A surge in the retail business, which provides enhanced access to products, is expected to boost the segment growth during the forecast period. Growing customer sophistication and demand for better value are also anticipated to create growth opportunities in the upcoming years that would lead to growth of this segment.
Start-ups help in determining the future growth opportunities in any market. These new entrants have the potential to generate high returns which directly benefits the expansion of any industry. These start-ups are typically more efficient at transforming inputs into outputs with more flexibility and adaptability in nature, able to shift quickly in response to sensitive market conditions. Some of the start-ups that will bolster the expansion of Urinary retention therapeutics market are:
The urinary retention therapeutics market is extremely competitive and consists of numerous key industry players. These players are innovating novel delivery systems for treating Urinary retention disorder. This is expected to propel Urinary retention therapeutics market. The key players in this market are: Lupin, Marksans Pharma, Zydus Cadila, Sun Pharmaceutical Industries Ltd, Torrent Pharmaceuticals Ltd, Teva Pharmaceutical Industries Ltd, Aurobindo Pharma, Apotex Inc, Ajanta Pharma, Breckenridge Pharmaceutical, Inc., Alembic Pharmaceuticals Limited, and Inventia Healthcare Limited.
Key industry players are inclined on adoption of inorganic growth strategies like acquisition, mergers, partnerships, and collaboration in order to strengthen their product portfolio. This is anticipated to fuel the global Urinary retention therapeutics market.
Report Attribute | Details |
---|---|
Market Value in 2023 | US$ 3.44 billion |
Market Value in 2033 | US$ 7.5 billion |
Growth Rate | CAGR of 8.11% from 2023 to 2033 |
Base Year for Estimation | 2022 |
Historical Data | 2018 to 2022 |
Forecast Period | 2023 to 2033 |
Quantitative Units | Revenue in US$ billion and CAGR from 2023 to 2033 |
Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
Segments Covered |
|
Regions Covered |
|
Key Countries Profiled |
|
Key Companies Profiled |
|
Customization | Available Upon Request |
The worldwide market is expected to be valued at US$ 3.44 billion in 2023.
Lupin, Marksans Pharma and Zydus Cadila are key urinary retention therapeutics industry players.
The worldwide market is expected to reach US$ 7.5 billion by 2033.
Growing demand for advanced, non-intrusive OTC devices and wearables is fueling market growth.
The stress urinary incontinence type is likely to remain the key segment in the market through 2033.
1. Executive Summary | Urinary Retention Therapeutics Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033 5.3.1. Anticholinergic/Antispasmodic Agents 5.3.2. Skeletal Muscle Relaxants 5.3.3. Antidepressants 5.3.4. Alpha Blockers 5.3.5. Topical Estrogens 5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Incontinence Type 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Incontinence Type, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Incontinence Type, 2023 to 2033 6.3.1. Urge Incontinence 6.3.2. Stress Incontinence 6.3.3. Over-flow Incontinence 6.3.4. Mixed Incontinence 6.4. Y-o-Y Growth Trend Analysis By Incontinence Type, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Incontinence Type, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel , 2018 to 2022 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel , 2023 to 2033 7.3.1. Hospital Pharmacy 7.3.2. Retail Pharmacy 7.3.3. Online Pharmacy 7.4. Y-o-Y Growth Trend Analysis By Distribution Channel , 2018 to 2022 7.5. Absolute $ Opportunity Analysis By Distribution Channel , 2023 to 2033 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 8.3.1. North America 8.3.2. Latin America 8.3.3. Europe 8.3.4. South Asia 8.3.5. East Asia 8.3.6. Oceania 8.3.7. MIDDLE EAST AND AFRICA 8.4. Market Attractiveness Analysis By Region 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. The USA 9.2.1.2. Canada 9.2.2. By Drug Class 9.2.3. By Incontinence Type 9.2.4. By Distribution Channel 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Drug Class 9.3.3. By Incontinence Type 9.3.4. By Distribution Channel 9.4. Key Takeaways 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Rest of Latin America 10.2.2. By Drug Class 10.2.3. By Incontinence Type 10.2.4. By Distribution Channel 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Drug Class 10.3.3. By Incontinence Type 10.3.4. By Distribution Channel 10.4. Key Takeaways 11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. United Kingdom (UK) 11.2.1.3. France 11.2.1.4. Spain 11.2.1.5. Italy 11.2.1.6. Rest of Europe 11.2.2. By Drug Class 11.2.3. By Incontinence Type 11.2.4. By Distribution Channel 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Drug Class 11.3.3. By Incontinence Type 11.3.4. By Distribution Channel 11.4. Key Takeaways 12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. India 12.2.1.2. Malaysia 12.2.1.3. Singapore 12.2.1.4. Thailand 12.2.1.5. Rest of South Asia 12.2.2. By Drug Class 12.2.3. By Incontinence Type 12.2.4. By Distribution Channel 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Drug Class 12.3.3. By Incontinence Type 12.3.4. By Distribution Channel 12.4. Key Takeaways 13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. China 13.2.1.2. Japan 13.2.1.3. South Korea 13.2.2. By Drug Class 13.2.3. By Incontinence Type 13.2.4. By Distribution Channel 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Drug Class 13.3.3. By Incontinence Type 13.3.4. By Distribution Channel 13.4. Key Takeaways 14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. Australia 14.2.1.2. New Zealand 14.2.2. By Drug Class 14.2.3. By Incontinence Type 14.2.4. By Distribution Channel 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Drug Class 14.3.3. By Incontinence Type 14.3.4. By Distribution Channel 14.4. Key Takeaways 15. MIDDLE EAST AND AFRICA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 15.2.1. By Country 15.2.1.1. GCC Countries 15.2.1.2. South Africa 15.2.1.3. Israel 15.2.1.4. Rest of MIDDLE EAST AND AFRICA 15.2.2. By Drug Class 15.2.3. By Incontinence Type 15.2.4. By Distribution Channel 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Drug Class 15.3.3. By Incontinence Type 15.3.4. By Distribution Channel 15.4. Key Takeaways 16. Key Countries Market Analysis 16.1. USA 16.1.1. Pricing Analysis 16.1.2. Market Share Analysis, 2022 16.1.2.1. By Drug Class 16.1.2.2. By Incontinence Type 16.1.2.3. By Distribution Channel 16.2. Canada 16.2.1. Pricing Analysis 16.2.2. Market Share Analysis, 2022 16.2.2.1. By Drug Class 16.2.2.2. By Incontinence Type 16.2.2.3. By Distribution Channel 16.3. Brazil 16.3.1. Pricing Analysis 16.3.2. Market Share Analysis, 2022 16.3.2.1. By Drug Class 16.3.2.2. By Incontinence Type 16.3.2.3. By Distribution Channel 16.4. Mexico 16.4.1. Pricing Analysis 16.4.2. Market Share Analysis, 2022 16.4.2.1. By Drug Class 16.4.2.2. By Incontinence Type 16.4.2.3. By Distribution Channel 16.5. Germany 16.5.1. Pricing Analysis 16.5.2. Market Share Analysis, 2022 16.5.2.1. By Drug Class 16.5.2.2. By Incontinence Type 16.5.2.3. By Distribution Channel 16.6. UK 16.6.1. Pricing Analysis 16.6.2. Market Share Analysis, 2022 16.6.2.1. By Drug Class 16.6.2.2. By Incontinence Type 16.6.2.3. By Distribution Channel 16.7. France 16.7.1. Pricing Analysis 16.7.2. Market Share Analysis, 2022 16.7.2.1. By Drug Class 16.7.2.2. By Incontinence Type 16.7.2.3. By Distribution Channel 16.8. Spain 16.8.1. Pricing Analysis 16.8.2. Market Share Analysis, 2022 16.8.2.1. By Drug Class 16.8.2.2. By Incontinence Type 16.8.2.3. By Distribution Channel 16.9. Italy 16.9.1. Pricing Analysis 16.9.2. Market Share Analysis, 2022 16.9.2.1. By Drug Class 16.9.2.2. By Incontinence Type 16.9.2.3. By Distribution Channel 16.10. India 16.10.1. Pricing Analysis 16.10.2. Market Share Analysis, 2022 16.10.2.1. By Drug Class 16.10.2.2. By Incontinence Type 16.10.2.3. By Distribution Channel 16.11. Malaysia 16.11.1. Pricing Analysis 16.11.2. Market Share Analysis, 2022 16.11.2.1. By Drug Class 16.11.2.2. By Incontinence Type 16.11.2.3. By Distribution Channel 16.12. Singapore 16.12.1. Pricing Analysis 16.12.2. Market Share Analysis, 2022 16.12.2.1. By Drug Class 16.12.2.2. By Incontinence Type 16.12.2.3. By Distribution Channel 16.13. Thailand 16.13.1. Pricing Analysis 16.13.2. Market Share Analysis, 2022 16.13.2.1. By Drug Class 16.13.2.2. By Incontinence Type 16.13.2.3. By Distribution Channel 16.14. China 16.14.1. Pricing Analysis 16.14.2. Market Share Analysis, 2022 16.14.2.1. By Drug Class 16.14.2.2. By Incontinence Type 16.14.2.3. By Distribution Channel 16.15. Japan 16.15.1. Pricing Analysis 16.15.2. Market Share Analysis, 2022 16.15.2.1. By Drug Class 16.15.2.2. By Incontinence Type 16.15.2.3. By Distribution Channel 16.16. South Korea 16.16.1. Pricing Analysis 16.16.2. Market Share Analysis, 2022 16.16.2.1. By Drug Class 16.16.2.2. By Incontinence Type 16.16.2.3. By Distribution Channel 16.17. Australia 16.17.1. Pricing Analysis 16.17.2. Market Share Analysis, 2022 16.17.2.1. By Drug Class 16.17.2.2. By Incontinence Type 16.17.2.3. By Distribution Channel 16.18. New Zealand 16.18.1. Pricing Analysis 16.18.2. Market Share Analysis, 2022 16.18.2.1. By Drug Class 16.18.2.2. By Incontinence Type 16.18.2.3. By Distribution Channel 16.19. GCC Countries 16.19.1. Pricing Analysis 16.19.2. Market Share Analysis, 2022 16.19.2.1. By Drug Class 16.19.2.2. By Incontinence Type 16.19.2.3. By Distribution Channel 16.20. South Africa 16.20.1. Pricing Analysis 16.20.2. Market Share Analysis, 2022 16.20.2.1. By Drug Class 16.20.2.2. By Incontinence Type 16.20.2.3. By Distribution Channel 16.21. Israel 16.21.1. Pricing Analysis 16.21.2. Market Share Analysis, 2022 16.21.2.1. By Drug Class 16.21.2.2. By Incontinence Type 16.21.2.3. By Distribution Channel 17. Market Structure Analysis 17.1. Competition Dashboard 17.2. Competition Benchmarking 17.3. Market Share Analysis of Top Players 17.3.1. By Regional 17.3.2. By Drug Class 17.3.3. By Incontinence Type 17.3.4. By Distribution Channel 18. Competition Analysis 18.1. Competition Deep Dive 18.1.1. Lupin 18.1.1.1. Overview 18.1.1.2. Product Portfolio 18.1.1.3. Profitability by Market Segments 18.1.1.4. Sales Footprint 18.1.1.5. Strategy Overview 18.1.1.5.1. Marketing Strategy 18.1.2. Marksans Pharma 18.1.2.1. Overview 18.1.2.2. Product Portfolio 18.1.2.3. Profitability by Market Segments 18.1.2.4. Sales Footprint 18.1.2.5. Strategy Overview 18.1.2.5.1. Marketing Strategy 18.1.3. Zydus Cadila 18.1.3.1. Overview 18.1.3.2. Product Portfolio 18.1.3.3. Profitability by Market Segments 18.1.3.4. Sales Footprint 18.1.3.5. Strategy Overview 18.1.3.5.1. Marketing Strategy 18.1.4. Sun Pharmaceutical Industries Ltd 18.1.4.1. Overview 18.1.4.2. Product Portfolio 18.1.4.3. Profitability by Market Segments 18.1.4.4. Sales Footprint 18.1.4.5. Strategy Overview 18.1.4.5.1. Marketing Strategy 18.1.5. Torrent Pharmaceuticals Ltd 18.1.5.1. Overview 18.1.5.2. Product Portfolio 18.1.5.3. Profitability by Market Segments 18.1.5.4. Sales Footprint 18.1.5.5. Strategy Overview 18.1.5.5.1. Marketing Strategy 18.1.6. Teva Pharmaceutical Industries Ltd 18.1.6.1. Overview 18.1.6.2. Product Portfolio 18.1.6.3. Profitability by Market Segments 18.1.6.4. Sales Footprint 18.1.6.5. Strategy Overview 18.1.6.5.1. Marketing Strategy 18.1.7. Aurobindo Pharma 18.1.7.1. Overview 18.1.7.2. Product Portfolio 18.1.7.3. Profitability by Market Segments 18.1.7.4. Sales Footprint 18.1.7.5. Strategy Overview 18.1.7.5.1. Marketing Strategy 18.1.8. Apotex Inc 18.1.8.1. Overview 18.1.8.2. Product Portfolio 18.1.8.3. Profitability by Market Segments 18.1.8.4. Sales Footprint 18.1.8.5. Strategy Overview 18.1.8.5.1. Marketing Strategy 18.1.9. Ajanta Pharma 18.1.9.1. Overview 18.1.9.2. Product Portfolio 18.1.9.3. Profitability by Market Segments 18.1.9.4. Sales Footprint 18.1.9.5. Strategy Overview 18.1.9.5.1. Marketing Strategy 18.1.10. Breckenridge Pharmaceutical, Inc 18.1.10.1. Overview 18.1.10.2. Product Portfolio 18.1.10.3. Profitability by Market Segments 18.1.10.4. Sales Footprint 18.1.10.5. Strategy Overview 18.1.10.5.1. Marketing Strategy 18.1.11. Alembic Pharmaceuticals Limited 18.1.11.1. Overview 18.1.11.2. Product Portfolio 18.1.11.3. Profitability by Market Segments 18.1.11.4. Sales Footprint 18.1.11.5. Strategy Overview 18.1.11.5.1. Marketing Strategy 18.1.12. Inventia Helthcare Limited 18.1.12.1. Overview 18.1.12.2. Product Portfolio 18.1.12.3. Profitability by Market Segments 18.1.12.4. Sales Footprint 18.1.12.5. Strategy Overview 18.1.12.5.1. Marketing Strategy 19. Assumptions & Acronyms Used 20. Research Methodology
Healthcare
June 2019
REP-GB-1340
January 2024
218 pages
Healthcare
September 2024
REP-GB-1451
Upcoming
Explore Healthcare Insights
View Reports